Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 26, Number 9—September 2020
Letter

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020

Suggested citation for this article

To the Editor: Sandhu et al. (1) reported 9 patients who were co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Clostridioides difficile. C. difficile infection (CDI) can be a co-occurrence or result of antimicrobial drug overuse and is potentially a complication of coronavirus disease (COVID-19). We report a 52-year-old man with hypertension who had fever, respiratory symptoms, abdominal pain, and diarrhea for 3 days. At admission to Saint Michael’s Medical Center (Newark, New Jersey, USA), he had a temperature of 101.8°F but was otherwise hemodynamically stable. He had an elevated absolute lymphocyte count (700 cells/μL), indicating lymphopenia. He tested positive for SARS-CoV-2 RNA by reverse transcription PCR and had elevated inflammatory markers on blood profile. He tested positive for C. difficile toxin and antigen at admission. He did not use antimicrobial drugs or proton pump inhibitors and had no known contacts with persons with diarrhea. He was mechanically ventilated and received oral vancomycin, intravenous metronidazole, and vasopressors. He died of respiratory failure and septic shock. In comparison to the patients described by Sandhu et al., the patient we report was younger and did not have a history of antimicrobial use.

SARS-CoV-2 has multifaceted presentations. Angiotensin-converting enzyme 2 receptor, which can act as a receptor for severe acute respiratory syndrome coronavirus, is expressed not only in alveolar cells but also in the gastrointestinal tract, including colonic cells (2,3). Diarrhea associated with COVID-19 might erode the normal microbial flora of the gut, leading to increased risk for CDI. Also, COVID-19 might weaken the immune system, leaving the patient vulnerable to CDI. COVID-19 patients produce inadequate interferon-γ and have defective macrophage activation and function, resulting in a dysregulated immune response (4). Interleukin-12 and interferon-γ are components of cell-mediated immunity. Interferon-γ produced by T-helper cells induces macrophages to destroy bacteria such as C. difficile (5).

The relationship between SARS-CoV-2 and CDI is still poorly understood. CDI might be a complication of COVID-19; however, we could not exclude the possibility of co-occurrence of CDI with COVID-19. Physicians should consider CDI when encountering a COVID-19 patient with diarrhea.

Top

Saraswathi Lakkasani, Kok Hoe ChanComments to Author , and Hamid S. Shaaban

Author affiliations: New York Medical College, Newark, New Jersey, USA

Top

References

  1. Sandhu  A, Tillotson  G, Polistico  J, Salimnia  H, Cranis  M, Moshos  J, et al. Clostridiodes difficile in COVID-19 patients, Detroit, Michigan, USA, March–April 2020. Emerg Infect Dis. 2020;26. DOIPubMed
  2. Li  W, Moore  MJ, Vasilieva  N, Sui  J, Wong  SK, Berne  MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:4504. DOIPubMed
  3. Hamming  I, Timens  W, Bulthuis  MLC, Lely  AT, Navis  G, van Goor  H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:6317. DOIPubMed
  4. Blanco-Melo  D, Nilsson-Payant  BE, Liu  WC, Uhl  S, Hoagland  D, Møller  R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:10361045.e9. DOIPubMed
  5. Cruz-Adalia  A, Veiga  E. Close encounters of lymphoid cells and bacteria. Front Immunol. 2016;7:405. DOIPubMed

Top

Suggested citation for this article: Lakkasani S, Chan KH, Shaaban HS. Clostridiodes difficile in COVID-19 patients, Detroit, Michigan, USA, March–April 2020. Emerg Infect Dis. 2020 Sep [date cited]. https://doi.org/10.3201/eid2609.202505

DOI: 10.3201/eid2609.202505

Original Publication Date: July 03, 2020

Related Links

Top

Table of Contents – Volume 26, Number 9—September 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Kok Hoe Chan, Saint Michael’s Medical Center, Newark, NJ 07101, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: June 17, 2020
Page updated: July 03, 2020
Page reviewed: July 03, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external